Sold by: Next Move Strategy Consulting
Deployed on AWS
The projected size of the Global Cancer Gene Therapy Market is anticipated to reach $558 billion by 2030, exhibiting a remarkable Compound Annual Growth Rate (CAGR) of 33% from 2024 to 2030. In light of this prevalent health challenge, the global cancer gene therapy market is experiencing robust growth.
Overview
The global Cancer Gene Therapy Market size is predicted to reach $558 billion, with a CAGR of 32.6% by 2030.
Gene therapy is a technique to treat or prevent diseases, by using specific genes to replace the mutated gene causing disease or inactivate the mutated gene not functioning properly, or introducing an entirely new gene into the body of patients to assist in fighting the disease.
Get a FREE Sample: https://www.nextmsc.com/cancer-gene-therapy-market/request-sample
Cancer gene therapy is gaining momentum due to high success rates achieved during pre-clinical and clinical trials. There are several experiments and researches going on to replace the use of conventional drugs and surgeries with gene therapy to treat cancer; as it causes least side effects and offers maximum efficacy.
Furthermore, improving regulatory standards regarding the quality of products utilized in gene therapy, growing investments for Research and Development activities, growing popularity of DNA vaccines, and ethical acceptance of the gene therapy treatments in treating cancer, are the factors anticipated in propagating growth of the global cancer gene therapy market, throughout the forecast period.
However, factors such as cost-effectiveness of the of gene therapy treatment, unwanted immune responses, and risk factors associated with the treatment, are expected to hamper the growth of cancer gene therapy market during the forecast period.
Inquire Before Buying: https://www.nextmsc.com/cancer-gene-therapy-market/inquire-before-buying
Moreover, growing geriatric population world-wide, increase In per-capita disposable incomes, advancements in product technologies, as well as untapped market opportunities offered by the emerging economies, are the factors anticipated in creating lucrative opportunities for the growth of cancer gene therapy market, coming future.
The cancer gene therapy market share has been analyzed based on therapy, end-user, and geography. Based on therapy, the cancer gene therapy market is classified into gene induced immunotherapy, gene transfer, and oncolytic virotherapy. The gene induced immunotherapy is further sub-segmented into the delivery of cytokines gene and delivery of tumor antigen gene.
The oncolytic virotherapy segment is further sub-segmented into adenovirus, lentivirus, vaccinia virus, herpes simplex virus, alpha virus, retro virus, adeno associated virus, simian virus, and others. Based on application, the cancer gene therapy market is divided into hospitals, diagnostics centers, and research institutes. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
North America region dominated the global cancer gene therapy market in the past, and is expected to maintain its dominance throughout the forecast period, accounting for the highest market share. The growing number of geriatric populations, well-established health-care infrastructures with specialized medical practitioners, advanced technological developments at the product front, presence of major manufactures and key players as well as higher adoption of cancer gene therapy treatment in this region, are the factors expected to boost-up the cancer gene therapy market growth.
Asia Pacific region is expected to demonstrate a substantial growth in the cancer gene therapy market, with considerable CAGR values throughout the forecast period. Increasing consumer awareness about cancer gene therapy, increasing government initiatives in propagating this treatment, improvement in healthcare infrastructures as well as untapped market offered by emerging economies, are further expected to propel the growth of cancer gene therapy market.
Comprehensive competitive analysis and profiles of the major market players such as Bluebird bio, Inc., Merck, Adaptimmune, GlaxoSmithKline, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Celgene, Shanghai Sunway Biotech, OncoGenex Pharmaceuticals, and others are provided in the cancer gene therapy market report.
Access Full Report: https://www.nextmsc.com/report/cancer-gene-therapy-market
An upsurge in Research and Development activities and advancement in product technologies and new product launches by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global cancer gene therapy market.
Contact Us:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +1-217-650-7991
Website: https://www.nextmsc.com/
Details
Delivery method
Deployed on AWS
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
This product is available free of charge. Free subscriptions have no end date and may be canceled any time.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Dimensions summary
This listing offers a single pricing option: Product Access, measured in units. It grants you access to the market research report at no charge. There are no tiers, sizes, or usage add-ons to choose between. Once your access is confirmed, the report is delivered digitally by email as a downloadable file, typically within 24 to 48 hours. Because the pricing model is Free, you pay nothing for this access dimension.
Top-of-mind questions for buyers
One unit grants you access to this single market research report on cancer gene therapy trends and projections. It covers the report content itself, not separate seats or user counts. You receive the report digitally after your access is confirmed.
The report is delivered by email to your registered address as a downloadable file, usually within 24 to 48 hours of confirmation. Delivery times may vary if customization is requested. Reports come in digital formats such as PDF, Excel, or Word.
No. All sales are final once the report is delivered. The vendor does not accept cancellations, returns, or refunds after purchase, since reports are digital and contain sensitive research data. Review all details before confirming your access.
www.nextmsc.com+1
Helpful?
Vendor refund policy
Not applicable - product available free of charge.
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
NMSC_MarketResearch | All historical revisions | All future revisions | Not included | Not included |
Resources
Vendor resources
Similar products
In Vivo CRO services support pharmaceutical research by conducting in vivo studies on animals to evaluate drug safety efficacy and pharmacokinetics. The market is expected to grow to 10.96 billion USD by 2030 at a compound annual growth rate of 9 percent from 2025 onward fueled by rising chronic diseases and healthcare advancements.
Machine Learning model to classify subjects’ susceptibility to lung cancer based on demographics, clinical measures and behavioral features.
Deep Learning model to predict the eligibility of a patient for a cancer clinical trial after going through patient's diagnosis notes.
Classifies fine-needle aspirates (FNA) of breast mass as benign or malignant
Identify risk of being diagnosed with Breast Cancer
Machine Learning model to predict the feasibility of a Clinical Trial